Moleculin Biotech Inc buy fchar99
Summary
This prediction ended on 18.07.17 with a price of €11.18. The BUY prediction by fchar99 for Moleculin Biotech Inc saw massive gains of 33.26%. fchar99 has 50% into this predictionMoleculin Biotech (Symbol: MBRX) is a clinical-stage pharmaceutical company focused on discovering, developing, and commercializing a broad range of innovative cancer treatments. With a diversified portfolio of drug candidates targeting difficult-to-treat cancers, including leukemia, lung, and pancreatic tumors, MBRX leverages cutting-edge scientific research and expertise to develop drugs that aim to provide improved patient outcomes. The company's innovative approach includes utilizing metabolic inhibitors, immune-globulin-like transcript 3 (ILT3) inhibitors, and STAT3 inhibitors as key weapons in the fight against cancer. As Moleculin Biotech advances its drug candidates through clinical trials, it holds the promise of bringing novel cancer therapies to market, potentially improving the lives of cancer patients globally.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Moleculin Biotech Inc | - | - | - | - |
iShares Core DAX® | 2.275% | 4.627% | 18.839% | 16.367% |
iShares Nasdaq 100 | 6.015% | 2.007% | 23.636% | 35.232% |
iShares Nikkei 225® | 4.456% | 3.598% | 12.437% | -0.660% |
iShares S&P 500 | 4.061% | 2.876% | 23.447% | 38.511% |
Comments by fchar99 for this prediction
In the thread Moleculin Biotech Inc diskutieren
fchar99 stimmt der Buy-Einschätzung von melinda zu
fchar99 stimmt am 11.07.2017 der Buy-Einschätzung von melinda mit dem Kursziel 2.0$ zu.Überschrift: cancer pancreas